Thymosin Alpha-1 + Thymalin Protocol

Unregulated

Also known as: TA1/Thymalin Stack, Immune Peptide Protocol, Khavinson Immune Stack

Immune Support

Last reviewed: April 28, 2026

A combination protocol pairing Thymosin Alpha-1 (a 28-amino acid thymic peptide) with Thymalin (a thymic extract) for comprehensive immune system modulation. Based on the work of Vladimir Khavinson, this stack targets both innate and adaptive immunity. Used in integrative medicine for immune optimization, post-illness recovery, and longevity protocols.

Mechanism of Action

Thymosin Alpha-1 activates dendritic cells, enhances T-cell maturation, and modulates Th1/Th2 balance. Thymalin provides a broader spectrum of thymic peptides that support thymic function and T-cell diversity. Together, they address both the specific (TA1) and general (Thymalin) aspects of thymic immune regulation.

Common Uses

  • Comprehensive immune optimization
  • Post-viral recovery protocols
  • Chronic infection support
  • Longevity and immune aging (immunosenescence)
  • Pre-travel immune preparation

Known Risks

  • Injection site reactions from both peptides
  • Potential for immune overstimulation
  • Autoimmune flare risk in predisposed individuals
  • Cost — both peptides required
  • Limited data on combination safety

Regulatory Status

Unregulated

Thymosin Alpha-1 is FDA-approved internationally (Zadaxin) but not in the US. Thymalin has no FDA status. The combination protocol is not FDA-reviewed. Both are available through compounding pharmacies. TA1 is on the 503A Category 1 bulks list.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Subcutaneous injection (both)

Typical Dose

TA1: 1.6 mg + Thymalin: 10 mg

Frequency

TA1: daily or every other day; Thymalin: daily for 10 days

Cycle Length

TA1: 2–4 weeks; Thymalin: 10-day course every 6 months

Khavinson protocol: Thymalin 10 mg daily for 10 days, repeated every 6 months. TA1 can be used continuously or in 2–4 week pulses. Inject at different sites. Some practitioners add Pinealon for a full Khavinson bioregulator stack. Monitor CBC and immune markers.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.